CVIR Endovascular’s Post

Through our Phase 2b/3 clinical trial, we are investigating a potential new treatment option that aims to lessen the burden of #ThyroidEyeDisease. Learn more about LIDS: https://lnkd.in/e4xE8anj

This meta-analysis demonstrated acceptable feasibility for no-option CLTI at highly specialised institutions for patients undergoing pDVA. Meta-analysis of time to event outcomes revealed that pDVA provides reasonable amputation free survival for up to 12 months, albeit with a overall low certainty of evidence. Wider adoption of pDVA may be considered in selective patients with CLTI, although its clinical impact and cost effectiveness require further evaluation.

Characterization of patients with atypical HUS and associated triggers or clinical conditions: A Global aHUS Registry analysis https://lnkd.in/eprC6QpR Think #aHUS when considering #TMA diagnostics.

Geographic Atrophy can greatly impact patients’ functioning and quality of life and limit their independence by interfering with activities of daily living, including difficulties with reading, driving, watching television, recognizing faces, and being unable to do household chores. No treatment became available until intravitreal pegcetacoplan was recently approved by the US Food and Drug Administration for GA secondary to AMD. In Europe there is no approved treatment. The design of clinical trials that lead to the approval of new medicines requires well-defined clinical endpoints. I am pleased to share this recent article “Informing Endpoints for Clinical Trials of Geographic Atrophy” in which I had the privilege of co-authoring. https://lnkd.in/djXxmNab

Unlock accurate, repeatable, and precise PD-L1 CTC insights with ANGLE. Accelerate your research with: • Highly accurate, repeatable and precise PDL1 CTC insights   • Minimally invasive, longitudinal monitoring of PDL1 status on variety of CTCs   • Early competitive advantage by understanding therapeutic response sooner   • Optimised patient selection   • Reduced trial size costs and time Discover ANGLE's end-to-end PDL1 CTC testing solution: https://lnkd.in/eSFcEuMk #PrecisionOncology #TranslationalMedicine #LiquidBiopsy For Research Use Only. Not for Use In Diagnostic Procedures.

🔸 “Patients need to be involved in trial design to refine the right questions” – Prof. Michael speaks about the role of patients in clinical trials design in a video recoded especially for INCA. 📲 Watch the insights of a prominent NET investigator: https://lnkd.in/daxsR6dW ☑ Find a NET clinical trial close to you with a few clicks: https://lnkd.in/dABv_heE Ancora.ai NORCAL CARCINET SUPPORT GROUP  #LetsTalkAboutNETs #NeuroendocrineCancer #clinical trials 

📢 Decision-making in weaning adult cardiogenic shock patients from VA #ECMO?? Clinical decision making regarding #ECLS liberation challenging and requires a well-structured weaning approach: to improve and harmonize this complex decision process, here a novel type of survey embedded into a clinical discrete choice modeling experiment. Participate to improve insights into the process of weighing multiple factors in complex weaning decisions. 🖋️ Join this 20-minute survey, approved by EuroELSO Steering Committee. 🔗 https://lnkd.in/d_Ba2ihf

[STA®-Liatest® D-Di Plus to enhance VTE diagnostis and patient care] 💡 23% of samples with a positive Siemens result were negative when tested with Stago. This data highlights the potential of Stago D-Dimer Tests to reduce unnecessary investigations and improve clinical decisions for patients with suspected VTE (Venous ThromboEmbolism). A recent study from The New Zealand Medical Journal compared 2️⃣ D-dimer assays: INNOVANCE® DDimer (Siemens) and STA®-Liatest® D-Di Plus (Stago) 👉 https://lnkd.in/egrxWnNw 🔎 Stago assay also showed better resistance to antibody interference, ensuring more reliable and accurate results. By using STA®-Liatest® D-Di Plus, healthcare providers can enhance VTE diagnostis and patient care. 👉 https://lnkd.in/ep7ca73K #Diagnostics #Healthcare #VTE #DDimer #PatientCare DAVID COURTOIS Alex S. Aliénor Auby Tara Simpson, MBA Nichole Howard, MBA Paul Riley Clémence Chesne Hadison Yip Yannig QUEREL

In patients with primary hyperparathyroidism, first-line F18-choline PET/CT is a suitable and safe replacement for MIBI SPECT/CT, finds randomized clinical trial. https://ja.ma/4cljYgG

POCTA has been advocating for the Molecular Diagnostic Services Program (MoIDX) to clarify that CLIA-waived labs are not required to register and obtain a Z-code for CLIA-waived tests. After a request from POCTA, we are pleased to announce that MolDX has issued an updated FAQ in which they confirm that CLIA-waived labs are not required to register or obtain a Z-code for CLIA-waived tests. This is important for point of care (POC) testing because previously, many POC labs believed they would need to register and obtain a Z-code, which would have placed an additional administrative burden on these important health care providers. Read the updated MoIDX FAQ here: https://lnkd.in/eaDbj7td #pointofcaretesting